September 15, 2017
Grid Therapeutics Closes Series A Financing
DURHAM, N.C.–(BUSINESS WIRE)–Grid Therapeutics, LLC, a biotechnology company developing the first human derived targeted immunotherapy for cancer, today announced the closing of its Series A financing. Grid will use the proceeds from the financing to fund the antibody production and Phase 1 clinical trial of its lead candidate for the treatment of solid tumors. Grid’s Series A financing was led by Longview International, Ltd., a Singapore-based venture capital firm with a well-established track record of investing in life science companies capable of producing transformative technologies. Duke University joins Longview International as another strategic shareholder.